Search

Muscovy duck-origin goose parvovirus (MDGPV) is a new virus resulting from the natural recombination of Muscovy duck parvovirus (MDPV) and goose parvovirus (GPV). Previously identified MDGPV strains were found to have two recombination regions, one in the P9 promoter to the NS region and one in the VP3 gene, or only one recombination in the VP3 gene. In 2022, a novel strain of MDGPV known as 2022FZ was identified from China's mainland. Complete genome sequence analysis showed that there were three recombination regions in this strain: one located in the P9 promoter-NS (425–612 nt) region, one in the NS2 (1,483–1,824 nt) region, and one in the VP3 (3,124–4,248 nt) region, respectively. The recombination regions in the P9 promoter-NS, NS2, and VP3 genes were substituted with the relevant GPVs sequences, whereas the MDPV virulent strain served as the skeleton in this instance. In addition, the 2022FZ strain had multiple unique aa mutations in the NS protein and the VP protein. The Muscovy duckling challenge test showed that MDGPV-2022FZ is less pathogenic to Muscovy ducklings than two recombinant or sole recombinant MDGPV strains. For the first time, our study identified a three-region recombinant MDGPV strain and detected the novel recombination event in the NS2 gene. These results contribute to our understanding of the pathogenicity and genetic diversity of duck parvovirus. [ABSTRACT FROM AUTHOR]

A new disease designated as Pale liver disease (PLD) has been circulating in Chinese Muscovy duck flocks since 2014, which is characterized by fatigue, diarrhoea, sudden death and acute hepatitis with pale and haemorrhagic liver. In this study, the etiological agents of PLD were isolated, causing a significant cytopathic effect (CPE) by cell rounding. Virus particles were observed by transmission electron microscopic (TEM) observation. The same disease was reproduced by experimental infection with the isolate BG61. The whole genomes of isolates were 43,842 nt in length with a GC content of 47.11%, similar to French Muscovy duck adenovirus strain GR with a GC content of 46.08%. The isolates shared 99.71–99.95% and 93.31–93.33% identity with Chinese Muscovy duck adenovirus isolates and GR strain, respectively. The DNA polymerase gene of all Muscovy duck adenovirus strains formed a separate genetic lineage with 99.55–100% amino acid sequence identity. All Chinese Muscovy duck adenovirus isolates contained two fibre genes. In contrast, only one fibre gene was found in GR, the only representative strain in species Duck aviadenovirus B. Anti‐DAdV‐2 serum antibodies had a weak neutralizing activity against Chinese Muscovy duck adenovirus isolates. The phylogenetic trees of the complete genome, hexon and fibre proteins revealed that all Muscovy duck adenovirus strains formed a major genetic lineage consisting of two clades. Thus, both GR and Chinese Muscovy duck adenovirus strains were proposed to be included in the same species of Duck aviadenovirus B belonging to the genus Aviadenovirus. The species Duck aviadenovirus B included two serotypes or genotypes, such as GR, which represents the strain of serotype 1 or genotype 1 (DAdV B1) and Chinese Muscovy duck adenovirus strains, which belong to serotype 2 or genotype 2 (DAdV B2). [ABSTRACT FROM AUTHOR]

Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus‐like particle (VLP)‐based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS‐PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil‐adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post‐vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post‐boost. The protective efficacy of the maternal vaccine was 87.5%–100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS. [ABSTRACT FROM AUTHOR]